Q4 EPS Estimates for Zimmer Biomet Cut by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Zacks Research reduced their Q4 2025 earnings per share estimates for Zimmer Biomet in a report issued on Monday, November 25th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will post earnings of $2.37 per share for the quarter, down from their prior estimate of $2.38. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share.

A number of other research firms have also issued reports on ZBH. Canaccord Genuity Group dropped their target price on Zimmer Biomet from $120.00 to $115.00 and set a “hold” rating on the stock in a report on Tuesday, September 10th. Evercore ISI dropped their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Robert W. Baird dropped their target price on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Royal Bank of Canada boosted their target price on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a report on Monday, November 4th. Finally, JPMorgan Chase & Co. dropped their target price on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday, September 16th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $123.22.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $112.06 on Thursday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a twelve month low of $101.47 and a twelve month high of $133.90. The stock has a 50 day moving average of $107.07 and a two-hundred day moving average of $109.49. The stock has a market cap of $22.31 billion, a P/E ratio of 21.30, a P/E/G ratio of 2.03 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. During the same quarter in the previous year, the business earned $1.65 earnings per share. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis.

Institutional Trading of Zimmer Biomet

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kennedy Capital Management LLC purchased a new position in Zimmer Biomet during the first quarter worth about $1,837,000. iA Global Asset Management Inc. purchased a new position in Zimmer Biomet during the first quarter worth about $1,243,000. Plato Investment Management Ltd lifted its position in Zimmer Biomet by 839.4% during the first quarter. Plato Investment Management Ltd now owns 930 shares of the medical equipment provider’s stock worth $123,000 after buying an additional 831 shares during the period. Wahed Invest LLC lifted its position in Zimmer Biomet by 19.5% during the first quarter. Wahed Invest LLC now owns 4,120 shares of the medical equipment provider’s stock worth $544,000 after buying an additional 671 shares during the period. Finally, LRI Investments LLC purchased a new position in Zimmer Biomet during the first quarter worth about $68,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.